Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products. Founded in 2015, Gossamer Bio raised $230 million from Hillhouse Capital Group in 2018. Dr. Sheila Gujrathi is co-founder, president and CEO of Gossamer Bio, a new biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations in immunology, inflammation, fibrosis and oncology.
Dr. Gujrathi received her M.D. in the accelerated Honors Program in Medical Education and her B.S. in biomedical engineering with highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford.
She received additional training at University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program
https://www.youtube.com/watch?v=nx0I6W7zO_U
https://tptherapeutics.com/portfolio-item/sheila-gujrathi-m-d/#:~:text=Dr.,%2C inflammation%2C fibrosis and oncology.